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Abstract	
Epidemiological	data	associate	hypertension	with	a	predisposition	to	Alzheimer’s	disease	
(AD)	and	a	number	of	post-mortem	and	in	vivo	studies	also	demonstrate	that	hypertension	
increases	amyloid-beta	(Aβ)	pathology.	In	contrast	anti-hypertensive	medications	reportedly	
improve	cognition	and	decrease	the	risk	of	AD,	while	certain	classes	of	anti-hypertensive	
drugs	are	associated	with	decreased	AD-related	pathology.	We	investigated	the	effects	of	
hypertension	and	anti-hypertensive	treatment	on	Aβ	plaque	load	in	post-mortem	frontal	
cortex	in	AD.	Aβ	load	was	significantly	increased	in	hypertensive	(N	=	20)	relative	to	
normotensive	cases	(N	=	62)	and	was	also	significantly	higher	in	treated	(N	=	9)	than	
untreated	hypertensives	(N	=	11).	We	then	looked	into	mechanisms	by	which	hypertension	
and	treatment	might	increase	Aβ	load,	focusing	on	Aβ-synthesising	enzymes,	β-	and	γ-
secretase,	and	Aβ-degrading	enzymes,	angiotensin-converting	enzyme	(ACE),	insulin-
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degrading	enzyme	(IDE)	and	neprilysin.	ACE	and	IDE	protein	levels	were	significantly	lower	in	
hypertensive	(N	=	21)	than	normotensive	cases	(N	=	64),	perhaps	translating	to	decreased	
Aβ	catabolism	in	hypertensives.	ACE	level	was	significantly	higher	in	treated	(N	=	9)	than	
untreated	hypertensives	(N	=	12),	possibly	reflecting	feedback	upregulation	of	the	renin-
angiotensin	system.	Prospective	studies	in	larger	cohorts	stratified	according	to	anti-
hypertensive	drug	class	are	needed	to	confirm	these	initial	findings	and	to	elucidate	the	
interactions	between	hypertension,	anti-hypertensive	treatments	and	Aβ	metabolism.	
	
Keywords:	Alzheimer’s	disease,	amyloid	β	protein,	anti-hypertensive,	hypertension,	β-
secretase,	BACE,	γ-secretase,	angiotensin-converting	enzyme,	insulin-degrading	enzyme	
	
Abbreviations:	Aβ	=	amyloid-beta;	AβPP	=	amyloid-beta	precursor	protein;	ACE	=	
angiotensin-converting	enzyme;	ACEI	=	angiotensin-converting	enzyme	inhibitor;	AD	=	
Alzheimer’s	disease;	AngII	=	angiotensin	II;	ARB	=	angiotensin	receptor	blocker;	BBB	=	blood	
brain	barrier;	CCB	=	calcium	channel	blocker;	IDE	=	insulin-degrading	enzyme;	NEP	=	
neprilysin;	NFT	=	neurofibrillary	tangle	
	
Introduction	
Epidemiological	studies	suggest	that	midlife	hypertension	is	a	risk	factor	for	later	
development	of	Alzheimer’s	disease	(AD),	the	most	common	form	of	dementia	in	the	elderly	
[1,	2].	Although	the	mechanistic	links	between	hypertension	and	AD	remain	elusive,	there	is	
evidence	of	association	between	hypertension	and	the	classical	neuropathological	hallmarks	
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of	AD;	particularly	the	accumulation	of	Aβ	in	plaques.	In	the	Honolulu	Heart	
Program/Honolulu-Asia	aging	Study	cohort,	elevated	midlife	systolic	blood	pressure	(≥	160	
mm	Hg)	was	associated	with	a	significant	increase	in	the	number	of	neocortical	and	
hippocampal	Aβ	plaques	at	post-mortem	examination,	and	elevated	midlife	diastolic	blood	
pressure	(≥	95	mm	Hg)	was	associated	with	a	higher	number	of	neurofibrillary	tangles	
(NFTs)	in	the	hippocampus	[3].	Similar	associations	were	reported	in	other	post-mortem	
studies	[4,	5].	In	living	participants	with	or	without	dementia,	the	amount	of	cerebral	Aβ	
detectable	by	amyloid	positron	emission	tomography	(amyloid-PET)	increased	with	diastolic	
blood	pressure	[6]	and	was	significantly	greater	in	cognitively	normal	hypertensive	
participants	who	had	at	least	1	APOE	ε4	allele	[7],	an	established	risk	factor	for	AD	[8,	9].	
Plasma	Aβ42:Aβ40	ratio	(mainly	driven	by	Aβ40	level)	correlated	with	systolic	blood	
pressure	[10]	and	with	severity	of	white	matter	damage	[11],	which	predicts	the	incidence	
[12]	and	progression	of	decline	in	AD	[13].	Experimental	studies	in	mice	[14-16]	and	rats	[17]	
provided	further	evidence	that	hypertension	promotes	Aβ	accumulation.	
At	present	the	mechanism	by	which	hypertension	enhances	Aβ	accumulation	is	
unknown.	Hypertension	induced	by	infusion	of	angiotensin	II	(AngII)	did	not	alter	the	
expression	of	mRNAs	encoding	multiple	proteins	involved	in	Aβ	production:	the	α-
secretases	Adam9,	Adam10,	and	Adam17,	the	β-secretases	Bace1	and	Bace2	and	the	γ-
secretase	components	Psen1,	Psen2,	Aph1a,	Aph1b,	Psenen	and	Ncstn	[18]	in	C57/BL6	mice.	
However,	intravenous	infusion	of	AngII	enhanced	β-secretase	cleavage	of	amyloid-β	
precursor	protein	(AβPP)	in	Tg2576	mice,	which	overexpress	a	mutant	form	of	APP	bearing	
the	Swedish	mutation	(KM670/671NL)	[15].	Intracerebroventricular	infusion	of	AngII	in	adult	
wild-type	Sprague-Dawley	rats	increased	activity	of	Aβ	synthesising	enzymes	and	Aβ42	
production	and	also	increased	tau	phosphorylation,	and	all	of	which	was	inhibited	by	an	
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AngII	receptor	antagonist,	losartan	[19,	20].	Similarly	AngII	exposure	increased	β-secretase	
activity	in	Chinese	hamster	ovary	cells	producing	Aβ	[15].	
In	recent	years,	the	potential	protective	effect	of	anti-hypertensive	therapies	on	
cognitive	decline	and	AD	has	become	a	topic	of	increasing	interest	and	a	number	of	reviews	
have	attempted	to	evaluate	the	somewhat	inconsistent	evidence	from	longitudinal	cohort	
studies	and	clinical	trials	[21-23].	The	data	are	encouraging	and	discrepancies	between	the	
studies	mainly	concern	differential	effects	of	the	anti-hypertensive	drug	classes.	Fournier	et	
al	[23]	concluded	that	the	angiotensin	receptor	blockers	(ARBs)	and	dihydropyridine	calcium	
channel	blockers	(CCBs)	have	greater	protective	effects	than	do	angiotensin-converting	
enzyme	inhibitors	(ACEIs)	and	diuretics,	and	that	β-blockers	may	be	neutral	or	even	worsen	
cognitive	decline.	The	amount	of	cerebral	Aβ	detected	by	amyloid-PET	in	cognitively	normal	
adults	was	higher	in	those	with	untreated	hypertension	than	in	the	treated	or	normotensive	
participants	[7].	
There	is	also	evidence	from	post-mortem	studies	that	antihypertensive	treatment	
reduces	Aβ	plaque	pathology	[3,	5,	24].	In	one	of	these	studies,	Hajjar	et	al	[24]	found	less	
Aβ	deposition	after	treatment	with	ARBs	than	other	classes	of	anti-hypertensives	or	in	brain	
tissue	from	people	with	a	history	of	untreated	hypertension.	The	ARBs	valsartan	[25]	and	
candesartan	[26]	reduced	oligomerisation	of	Aβ	in	vitro,	as	did	the	diuretic	furosemide	and	
the	CCB	nitrendipine	[26],	while	the	ARBs	valsartan	[25]	and	losartan	[27]	reduced	Aβ	
plaque	formation	in	transgenic	mouse	models	of	Aβ	accumulation.	The	mechanism(s)	by	
which	anti-hypertensive	drugs	might	decrease	Aβ	accumulation	are	largely	unstudied.	Paris	
et	al	[28]	showed	that	dihydropyridine	CCBs	improved	Aβ	clearance	across	the	blood-brain	
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barrier	(BBB)	in	a	mouse	model	of	Aβ	accumulation	and	Wang	et	al	[25]	showed	that	ARB	
treatment	increased	activity	of	an	Aβ-degrading	enzyme,	insulin-degrading	enzyme	(IDE).	
In	this	study	of	post-mortem	tissue	we	initially	performed	a	retrospective	analysis	to	
investigate	whether	hypertension	and	anti-hypertensive	treatment	was	associated	with	Aβ	
plaque	load	in	the	frontal	cortex	of	a	series	of	AD	brains	in	which	the	plaque	load	had	been	
routinely	measured.	Since	there	is	some	evidence	for	a	relationship	between	APOE	
genotype	and	hypertension	[29],	we	included	an	analysis	of	APOE	ε4	allele	presence	or	
absence.	Our	finding	in	this	study	of	significantly	increased	Aβ	load	in	the	AD	cases	with	a	
history	of	hypertension	compared	to	normotensive	cases,	and	in	treated	than	untreated	
hypertensive	cases	guided	a	series	of	subsequent	investigations	of	possible	mechanisms	by	
which	hypertension	and	anti-hypertensive	treatment	might	have	increased	Aβ	production	or	
proteolytic	degradation.	In	particular,	we	investigated	the	following	with	respect	to	
hypertensive	status	and	treatment,	in	AD	and	neuropathologically	normal	controls:	activity	
of	β-	and	γ-secretases,	responsible	for	sequential	cleavage	of	AβPP	to	Aβ,	and	concentration	
and	activity	of	three	Aβ-degrading	enzymes,	neprilysin	(NEP)	[30-32],	IDE	[33,	34]	and	
angiotensin-converting	enzyme	(ACE)	[35,	36].	Levels	of	ACE	and	IDE	were	decreased	in	
cortex	from	people	with	a	history	of	hypertension,	suggesting	that	hypertension	may	affect	
Aβ	catabolism,	and	the	level	of	ACE	was	increased	in	cases	where	hypertension	was	treated,	
suggesting	feedback	upregulation	of	the	renin-angiotensin	system.	Prospective	studies	in	
larger	cohorts	stratified	according	to	anti-hypertensive	drug	class	are	needed	to	confirm	
these	initial	findings.	
	
Materials	and	Methods	
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Brain	tissue	
Brain	tissue	was	obtained	from	the	South	West	Dementia	Brain	Bank	(SWDBB),	University	of	
Bristol,	with	research	ethics	committee	approval	from	NRES	Committee	South	West	–	
Central	Bristol.	The	brains	had	been	divided	mid-sagittally	at	autopsy,	the	left	cerebral	
hemisphere	sliced	and	frozen	at	-80°C,	and	the	right	hemisphere	fixed	in	10%	buffered	
formalin	for	3	weeks	before	its	embedding	for	paraffin	histology.	All	cases	had	been	
subjected	to	detailed	neuropathological	assessment	and	diagnosis	had	been	made	following	
standard	protocols	[37,	38].	According	to	National	Institute	on	Aging-Alzheimer’s	
Association	guidelines,	AD	neuropathological	changes	were	a	sufficient	explanation	for	the	
dementia	in	all	of	the	AD	cases	[37]	and	the	controls	had	no	clinical	history	of	cognitive	
decline	and	showed	no	or	minimal	AD	changes	(up	to	Braak	tangle	stage	II)	or	other	
neuropathological	abnormalities.	
For	immunohistochemical	analysis	we	used	7-µm	paraffin	sections	from	the	right	
frontal	lobe.	For	biochemical	analysis,	frozen	tissue	(200	mg)	from	left	midfrontal	cortex	
(Brodmann	area	46)	was	homogenised	in	either	0.5%	Triton	X-100	lysis	buffer	or	1%	sodium	
dodecyl	sulphate	(SDS)	lysis	buffer	(see	individual	assays)	in	a	Precellys	24	homogeniser	
(Stretton	Scientific,	Derbyshire,	UK)	for	2	x	15	s	at	6000	x	g,	centrifuged	at	13,000	x	g	for	15	
min	at	4°C	and	stored	at	-80°C.	Total	protein	was	measured	using	the	Total	Protein	kit	
(Sigma	Aldrich).	
	
Study	cohorts	
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Diagnostic	criteria	for	retrospective	diagnosis	of	hypertension	were:	sustained	SBP	≥	140	
mm	Hg	and/or	DBP	≥	90	mm	Hg	recorded	on	three	or	more	occasions.	Cases	in	which	all	
blood	pressure	readings	recorded	in	the	medical	notes	were	within	the	normal	range	were	
classified	as	normotensive;	furthermore	these	cases	had	no	history	of	any	prescriptions	for	
anti-hypertensive	drugs.	The	hypertensive	cases	were	stratified	into	those	with	a	history	of	
anti-hypertensive	treatment	(prescription	of	one	or	more	anti-hypertensive	drugs	listed	in	
the	medical	records)	and	an	untreated	group	(no	history	of	any	anti-hypertensive	drug	
prescriptions).	MRC	database	identifiers,	pathological	and	demographic	data	and	details	of	
measurements	available	for	individual	cases	are	listed	in	Supplementary	Table	1.	
	
Measurement	of	Aβ	plaque	load		
For	initial	analysis,	we	used	measurements	of	frontal	Aβ	plaque	load	that	had	previously	
been	determined	in	82	AD	brains:	62	cases	from	normotensive	patients	and	20	from	
patients	with	a	history	of	hypertension.	Of	the	hypertensive	cases,	only	9	had	been	treated.	
Age	and	post-mortem	delay	did	not	differ	significantly	between	the	groups	used	for	pairwise	
comparisons.	Previous	studies	by	our	group	found	no	effect	of	simulated	post-mortem	delay	
of	up	to	72	h	on	Aβ	measurements	[39].	Braak	tangle	stage	was	not	significantly	different	
between	groups	used	for	pairwise	comparisons;	however	the	normotensive	group	tended	to	
include	more	cases	with	lower	Braak	tangle	pathology	(including	3	cases	with	Braak	tangle	
stage	III)	(Supplementary	Figure	1).	Demographic	data	for	this	cohort	are	summarised	in	
Table	1.	
The	field	fraction	(percentage	area)	immunopositive	for	Aβ	(labelled	with	antibody	
to	Aβ	residues	17-24,	clone	4G8	from	BioLegend,	London,	UK;	1:16000	overnight	incubation	
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after	immersion	of	sections	in	formic	acid,	visualised	with	avidin-biotin	horseradish	
peroxidase	complex	kit	from	Vector	Laboratories,	Burlingame,	CA)	was	measured	in	10	areas	
of	cortex	covering	4	mm2.	Histometrix	software	(Kinetic	Imaging,	Wirral,	UK)	driving	a	Leica	
DM	microscope	with	a	motorised	stage	was	used	to	make	an	unbiased	selection	of	the	10	
areas,	as	previously	described	[40].	Aβ-laden	blood	vessels	were	excluded	from	analysis.	
	
Measurement	of	β-and	γ-secretase	activity	
Retrospective	analysis	of	β-secretase	and	prospective	analysis	of	γ-secretase	activity	was	
performed	in	108	brains	from	AD	and	neuropathologically	normal	controls:	77	cases	from	
normotensive	patients	(50	AD	and	27	controls)	and	31	from	patients	with	a	history	of	
hypertension	(18	AD	and	13	controls).	Frontal	Aβ	plaque	load	was	available	for	all	AD	cases.	
Of	the	hypertensive	cases,	13	had	been	treated.	Post-mortem	delay	did	not	differ	
significantly	between	groups	used	for	pairwise	comparisons	but	age	was	significantly	higher	
in	the	hypertensive	cohort.	Demographic	and	neuropathological	data	for	this	cohort	are	
summarised	in	Table	2.	
β-secretase	activity	had	been	measured	previously	[31,	41,	42].	As	described,	the	
fluorogenic	substrate	Mca-SEVNLDAEFRK(Dnp)RR-NH2	(R&D	Systems),	containing	part	of	
human	AβPP	sequence	modified	by	the	Swedish	double	mutation,	was	used	according	to	
the	manufacturer’s	guidelines	to	measure	β-secretase	activity	in	brain	homogenates	
prepared	in	0.5%	Triton	X-100	lysis	buffer	diluted	1:200	in	0.1	M	sodium	acetate	buffer	(pH	
4,	37°C).	Each	homogenate	was	assayed	in	duplicate	in	the	absence,	and	once	in	the	
presence,	of	the	β-secretase	inhibitor	III	(Millipore,	Durham,	UK,	5	mM).	Seven	two-fold	
serial	dilutions	of	recombinant	human	β-secretase	(R&D	Systems,	20000	–	156	ng/ml)	were	
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also	assayed,	in	the	absence	and	in	the	presence	of	β-secretase	inhibitor	III,	on	each	plate.	
After	a	3	h	incubation	at	37°C,	fluorescence	was	measured	by	excitation	at	320	and	emission	
at	405	nm	in	a	FLUOstar	Optima	plate	reader	(BMG	LABTECH	Ltd,	Aylesbury,	UK).	β-
secretase-specific	activity	was	determined	by	subtracting	the	fluorescent	signal	after	
inhibition	from	that	in	the	paired	uninhibited	wells.	β-secretase	activity	in	relative	
fluorescence	units	(rfu)	was	interpolated	from	the	standard	curve	and	adjusted	for	total	
protein	content.	
γ-secretase	activity	was	measured	in	the	same	homogenates.	The	fluorogenic	substrate	
Nma-GGVVIATVK(Dnp)DRDRDR-NH2	(Merk	Millipore,	Darmstadt,	Germany),	containing	the	C-
terminal	AβPP	amino	acid	sequence	that	is	cleaved	by	γ-secretase,	was	used	according	to	
the	manufacturer’s	guidelines	to	measure	γ-secretase	activity	in	brain	homogenates	
prepared	in	0.5%	Triton	X-100	lysis	buffer.	Brain	homogenates	were	diluted	1:50	in	0.1	M	
sodium	acetate	buffer	(pH	4,	37°C)	and	seven	two-fold	serial	dilutions	of	a	standard	
reference	brain	homogenate	were	included	on	each	plate.	Each	sample	was	assayed	in	
duplicate	in	the	absence,	and	once	in	the	presence,	of	two	γ-secretase-specific	inhibitors,	L-
685,	458	(Tocris	Bioscience,	Bristol,	UK,	100	μM)	and	DAPT	(N-[N-(3,5-Difluorophenacetyl-L-
alanyl)]-S-phenylglycine	t-butyl	ester	(Enzo	Life	Sciences,	Exeter,	UK,	200	μM)	in	black	F16	
Nunc	Maxisorp	plates	(Fisher	Scientific).	Following	a	2	h	incubation	at	37°C	(with	agitation,	
protected	from	light),	fluorescence	was	measured	by	excitation	at	360	and	emission	at	440	
nm	in	a	FLUOstar	Optima	plate	reader	(BMG	LABTECH	Ltd).	γ-secretase-specific	activity	was	
determined	by	subtracting	the	fluorescent	signal	after	inhibition	from	that	in	the	paired	
uninhibited	wells.	γ-secretase	activity	(in	rfu)	was	interpolated	from	the	standard	curve	and	
adjusted	for	total	protein	content.	The	mean	intra-assay	CV	was	4.41%	(s.d.	3.33)	and	the	
inter-assay	CV	was	7.64%	(s.d.	3.66).	
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Measurement	of	ACE,	IDE	and	NEP	concentration	and	activity	
Retrospective	analysis	of	ACE,	IDE	and	NEP	concentration	and	activity	was	performed	in	85	
brains	from	AD	and	neuropathologically	normal	controls:	64	cases	from	normotensive	
patients	(43	AD	and	21	controls)	and	21	from	patients	with	a	history	of	hypertension	(12	AD	
and	9	controls).	Frontal	Aβ	plaque	load	was	available	for	all	AD	cases.	Of	the	hypertensive	
cases,	9	had	been	treated.	Post-mortem	delay	did	not	differ	significantly	between	groups.	In	
previous	studies	by	our	group	ACE,	IDE	and	NEP	activities	were	found	to	be	stable	for	at	
least	72	h	under	conditions	of	simulated	post-mortem	delay	[34,	43].	Age	was	significantly	
higher	in	the	hypertensive	cohort.	Demographic	and	neuropathological	data	for	this	cohort	
are	summarised	in	Table	3.	
ACE,	IDE	and	NEP	protein	and	activity	in	these	cases	had	been	previously	measured	and	
published	[30,	31,	33-36,	41].	ACE	protein	had	been	measured	using	the	ACE	Duoset	ELISA	
kit	(R&D	systems)	and	ACE	activity	had	been	measured	using	the	ACE1-specific	fluorogenic	
substrate	Abz-FRK(Dnp)-P	(Biomol	International,	Exeter,	UK)	in	the	presence	of	captopril	(1	
mM)	in	brain	homogenates	prepared	in	1%	SDS	lysis	buffer,	as	detailed	in	Miners	et	al	[35,	
36].	IDE	protein	had	been	measured	by	sandwich	ELISA	with	rabbit	anti-human	IDE	capture	
antibody	(Abcam,	Cambridge,UK)	and	mouse	anti-IDE	detection	antibody	(R&D	Systems,	
Abingdon,	UK)	in	brain	homogenates	prepared	in	1%	SDS	lysis	buffer,	and	IDE	activity	had	
been	measured	using	an	immunocapture-based	assay	with	an	IDE-specific	capture	antibody	
(rabbit	polyclonal	anti-IDE,	Abcam)	and	the	fluorogenic	peptide	substrate	Mca-RPPGFSAFK-
OH	(R&D	Systems)	in	brain	homogenates	prepared	in	0.5%	Triton	X-100	lysis	buffer,	as	
detailed	in	Miners	et	al	[33,	34].	NEP	protein	had	been	measured	using	the	Neprilysin	
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Duoset	ELISA	kit	(R&D	systems)	in	brain	homogenates	prepared	in	1%	SDS	lysis	buffer,	and	
NEP	activity	had	been	measured	using	an	immunocapture-based	assay	with	a	NEP-specific	
capture	antibody	(goat	anti-human	NEP,	R&D	Systems)	and	the	fluorogenic	peptide	
substrate	Mca-RPPGFSAFK-OH	(R&D	Systems)	in	brain	homogenates	prepared	in	0.5%	Triton	
X-100	lysis	buffer,	as	detailed	in	Miners	et	al	[30-32].	
	
Statistical	analysis	
Pairwise	comparisons	between	groups	were	made	by	Mann-Whitney	U	test.	Spearman’s	
test	was	used	to	assess	correlations	between	post-mortem	delay	and	all	measured	proteins	
(for	results	see	Supplementary	Table	2).	Post-hoc	statistical	power	calculations	were	made	
using	G*Power	3.1.9.2	software	[44].	P	values	<	0.05	were	considered	statistically	
significant.	
	
Results	
Increased	frontal	Aβ	load	in	AD	with	history	of	hypertension		
Frontal	Aβ	load	was	significantly	higher	in	the	hypertensive	than	normotensive	AD	cases	(p	=	
0.020;	Figure	1	A).	Frontal	Aβ	load	tended,	although	not	significantly	so,	to	be	higher	in	
treated	than	untreated	hypertensive	cases	(p	=	0.07;	Figure	1	B).	In	this	cohort	possession	of	
APOE	ε4	was	associated	with	a	non-significantly	greater	frontal	Aβ	load.	Frontal	Aβ	load	was	
significantly	higher	in	the	ε4+	hypertensive	than	ε4+	normotensive	cases	(p	=	0.009)	
(Supplementary	Figure	2).	
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Aβ-synthesising	enzyme	activities	are	not	altered	in	AD	or	controls	with	history	of	
hypertension,	or	affected	by	anti-hypertensive	treatment	
β-	and	γ-secretase	activities	in	midfrontal	cortex	were	higher	in	AD	than	control	cases	(β-
secretase	p	=	0.031;	γ-secretase	p	=	0.058)	(Supplementary	Figure	3),	therefore	analysis	of	
the	influence	of	history	of	hypertension	was	performed	both	with	the	diagnosis	groups	
combined	and	also	separately	in	AD	and	controls.	β-	and	γ-secretase	activities	were	similar	
in	hypertensive	and	normotensive	cases,	and	in	treated	and	untreated	hypertensive	cases	in	
all	diagnosis	groups	(Figure	3).	
	
Hypertension,	anti-hypertensive	treatment	and	Aβ-degrading	enzymes	
Analysis	was	performed	both	with	diagnosis	groups	combined	and	also	separately	in	AD	and	
controls,	as	there	is	evidence	that	ACE,	IDE	and	NEP	are	altered	in	AD	[31].	Levels	and	
activities	of	ACE,	IDE	and	NEP	were	compared	between	hypertensive	and	normotensive	
groups	(Supplementary	Table	3).	ACE	protein	was	significantly	lower	in	the	combined	
hypertensive	group	(p	=	0.010)	and	in	hypertensive	AD	cases	(p	=	0.009)	but	not	
hypertensive	controls	(Figure	3A	–	C).	Similar	but	non-significant	trends	were	observed	for	
ACE	activity	(Figure	3D	–	F).	IDE	protein	was	significantly	lower	in	the	combined	hypertensive	
group	(p	=	0.036)	but	not	when	cases	were	stratified	according	to	diagnosis.	IDE	activity	was	
significantly	higher	in	hypertensive	controls	(p	=	0.027)	but	not	in	the	combined	or	AD	group	
(Figure	3	G	-	L).	NEP	protein	and	activity	did	not	differ	significantly	between	groups.	
Levels	and	activities	of	ACE,	IDE	and	NEP	were	also	compared	between	treated	and	untreated	
hypertensive	cases	(Supplementary	Table	4).	ACE	protein	was	significantly	higher	in	treated	cases	
with	diagnosis	groups	combined	(p	=	0.008)	and	in	treated	AD	cases	(p	=	0.016),	and	a	similar	trend	
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was	observed	in	treated	controls	(Figure	4	A	-	C).	However,	the	increases	in	ACE	protein	were	not	
reflected	in	ACE	activity	(Figure	4	D	–	F).	IDE	and	NEP	protein	and	activity	did	not	differ	significantly	
between	groups.	Post-hoc	analysis	estimating	the	power	of	the	test	to	reject	a	type	II	error	(reject	
the	hypothesis	falsely)	at	the	p	=	0.05	level	for	ACE	protein	between	hypertensive	and	normotensive	
groups	was	70%	in	the	combined	cohort	and	79%	in	the	AD	cohort.	For	ACE	protein	between	treated	
and	untreated	groups	the	figures	were	81%	in	the	combined	cohort	and	83%	in	the	AD	cohort.	
	
Discussion	
This	retrospective	study	has	shown	significantly	higher	frontal	Aβ	load	in	AD	cases	with	a	
history	of	hypertension,	in	keeping	with	prior	evidence	from	other	human	post-mortem	[3,	
4]	and	neuroimaging	studies	[6,	7],	and	studies	in	mice	[14-16]	and	rats	[17].	Although	Braak	
tangle	stage	did	not	differ	significantly	between	the	hypertensive	and	normotensive	group,	
the	hypertensive	group	did	tend	to	have	slightly	more	advanced	Braak	tangle	stages,	raising	
the	possibility	that	hypertension	may	also	exacerbate	this	aspect	of	AD	pathology	as	well.	
We	have	expanded	on	previous	studies	by	investigating	several	mechanisms	by	which	
hypertension	might	increase	Aβ	load,	focusing	on	the	synthesis	and	enzymatic	degradation	
of	Aβ.	
Our	findings	indicate	that	β-	and	γ-secretase	activities	are	unchanged	by	hypertensive	
status,	arguing	against	increased	Aβ	synthesis	as	an	explanation	for	increased	Aβ	load	in	
hypertensives.	This	is	in	keeping	with	a	study	in	mice	in	which	hypertension	induced	by	
infusion	of	AngII	had	no	effect	on	the	expression	of	AβPP	or	the	secretase	enzymes	[18],	but	
in	contrast	to	other	AngII	infusion	studies	in	mice	[15]	and	rats	[20].	Of	the	three	Aβ-
degrading	enzymes	we	investigated,	the	concentration	of	two	–	ACE	and	IDE	–was	
significantly	decreased	in	the	frontal	cortex	in	hypertensive	cases,	particularly	those	with	
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AD.	Although	we	did	not	find	that	the	activity	of	these	enzymes	was	significantly	reduced	in	
hypertension,	this	finding	raises	the	possibility	that	one	contributor	to	the	increased	Aβ	load	
in	hypertension	may	be	a	decrease	in	Aβ	catabolism.	Studies	that	have	shown	that	ACE	
converts	Aβ43	(recently	found	to	be	the	earliest	form	of	Aβ	deposited	in	a	mouse	model	of	
AD	[45])	to	Aβ41	[45],	and	Aβ42	to	the	less	amyloidogenic	form	Aβ40	[46,	47].	
In	this	study	we	examined	only	a	few	of	the	potential	contributors	to	increased	
accumulation	of	Aβ	in	AD.	Several	other	effects	of	hypertension	may	also	play	a	role.	These	
could	include	impaired	perivascular	drainage	as	a	consequence	of	collagenous	thickening	
and	reduced	pulsatility	of	arteries	and	arterioles	[48-50];	reduced	receptor-mediated	
transport	of	Aβ	across	the	endothelium	into	the	bloodstream;	degeneration	of	pericytes	
[51],	leading	to	reduced	clearance	of	soluble	Aβ40	and	Aβ42	from	the	interstitial	fluid	[52];	
altered	expression	of	AβPP	[53,	54];	or	reduction	in	the	activity	of	any	of	several	Aβ-
degrading	enzymes	other	than	those	measured	in	the	present	study	[55-57].	
In	previous	post-mortem	[3,	5,	24]	and	clinical	studies	[7],	anti-hypertensive	treatment	
was	reported	to	reduce	Aβ	pathology.	Unexpectedly,	we	found	frontal	Aβ	load	to	be	higher	
in	the	treated	than	untreated	hypertensives.	One	possible	explanation	is	that	treatment	was	
more	likely	to	be	prescribed	to	people	with	more	marked	or	more	persistent	hypertension.	
However,	there	were	several	limitations	to	the	present	study	that	should	be	considered	in	
interpreting	the	findings.	The	cohort	size	was	small,	particularly	that	of	the	treated	
hypertensive	group,	and	although	post-hoc	power	analyses	indicated	reasonable	statistical	
power,	this	type	of	power	calculation	cannot	be	used	to	support	findings	retrospectively.	
Furthermore,	the	retrospective	nature	of	the	study	imposed	multiple	constraints	on	the	
data	acquisition	and	quality	assurance:	in	many	cases	we	lacked	information	on	the	duration	
and	effectiveness	of	anti-hypertensive	treatment,	the	criteria	for	diagnosis	and	treatment	of	
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hypertension	have	changed	over	time,	and	there	was	inconsistency	in	the	way	in	which	
blood	pressure	was	measured	–	in	some	cases	automated,	in	others	manual.	A	final	
consideration	is	that	the	cohort	was	too	small	for	meaningful	stratification	of	cases	
according	to	anti-hypertensive	drug	class,	whilst	polypharmacy	(i.e.	being	on	more	than	one	
type	of	blood	pressure	drug	concurrently)	is	also	often	common.	We	noted	that	89%	of	
treated	cases	had	received	either	diuretics	or	β-blockers,	which	have	little	protective	effect	
on	cognition	and	may	even	exacerbate	cognitive	decline	[23],	and	33%	were	prescribed	ACE	
inhibitors,	which	were	found	to	have	ambiguous	effects	on	cognition	[23]	and	may	even	
increase	mortality	rate	in	AD	[22]).	Only	22%	were	prescribed	a	CCB	and	none	were	
prescribed	an	ARB,	the	drug	classes	shown	to	have	the	greatest	protective	potential	against	
AD	[23].	For	all	of	these	reasons,	and	the	reported	differential	effects	of	various	anti-
hypertensive	drugs	on	AD,	the	findings	on	subgroup	analysis	in	the	current	study	cannot	be	
taken	to	indicate	that	Aβ	accumulation	is	increased	by	treatment	of	hypertension	per	se.	
As	far	as	we	are	aware,	this	is	the	first	study	to	investigate	the	possible	influence	of	
anti-hypertensive	treatment	on	the	level	or	activity	of	Aβ-synthesising	and	-degrading	
enzymes	in	human	brain	tissue.	ACE	protein	level	in	the	frontal	cortex	was	significantly	
increased	in	treated	hypertensives,	particularly	in	the	AD	group.	Whilst	for	the	reasons	
discussed	above,	caution	is	warranted	in	interpreting	this	finding,	it	raises	the	possibility	
that	antihypertensive	therapy	may	cause	feedback	upregulation	of	ACE	production	within	
the	brain.	Although	this	is	unlikely	to	be	have	an	impact	on	the	control	of	blood	pressure,	it	
is	noteworthy	that	ACE	has	a	wide	range	of	substrates	and	probable	physiological	functions	
in	the	CNS	[58]	that	have	the	potential	to	be	affected	if	the	production	of	this	enzyme	is	
increased.	
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In	 conclusion	we	have	 shown	 that	 hypertension	 increases	 plaque-associated	Aβ	 in	
the	 frontal	 cortex.	 This	may	 be	 partly	 attributable	 to	 decreased	 Aβ	 catabolism	 but	 other	
mechanisms	are	 likely	 to	contribute	and	warrant	 further	 investigation.	Prospective	studies	
of	larger	cohorts	are	needed	to	assess	the	influence	of	different	classes	of	anti-hypertensive	
drug	on	Aβ	pathology,	and	the	impact	this	has	on	their	efficacy	in	reducing	cognitive	decline	
and	protecting	against	AD.	
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Figure	1.	Frontal	Aβ	load	(%)	in	AD	cases	with	and	without	hypertension	(A)	and	in	the	hypertensive	group	
stratified	into	treated	and	untreated	cases	(B).	Frontal	Aβ	load	was	significantly	higher	in	the	hypertensive	
group	(p	=	0.020)	and	was	also	higher	in	cases	that	had	been	treated	with	anti-hypertensives.	The	horizontal	
bars	indicate	the	mean	and	SEM.	Each	point	represents	a	separate	brain.	
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Figure	2.	A	–	C	and	D	–	F	show	β-	and	γ-secretase	activities	in	hypertensive	and	normotensive	cases,	and	G	–	I	
and	J	–	L	show	β-	and	γ-secretase	activities,	in	treated	and	untreated	hypertensives,	with	diagnosis	groups	
combined	(column	1),	in	AD	(column	2)	and	in	controls	(column	3).	β-	and	γ-secretase	activities	were	similar	in	
the	hypertensive	and	normotensive	groups	and	were	not	affected	by	anti-hypertensive	treatment.	The	
horizontal	bars	indicate	the	mean	and	SEM.	Each	point	represents	a	separate	brain.	
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Figure	3.	A	–	C	and	D	–	F	show	ACE	protein	and	activity,	and	G	–	I	and	J	–	L	show	IDE	protein	and	activity	with	
respect	to	hypertensive	status,	with	diagnosis	groups	combined	(column	1),	in	AD	(column	2)	and	controls	
(column	3).	ACE	protein	was	significantly	lower	in	hypertensive	cases	in	the	combined	diagnosis	(p	=	0.010)	
and	AD	groups	(p	=	0.009).	IDE	protein	was	significantly	lower	in	hypertensive	cases	in	the	combined	diagnosis	
group	(0.036)	and	IDE	activity	was	significantly	increased	in	hypertensive	control	cases	(p	=	0.027).	The	
horizontal	bars	indicate	the	mean	and	SEM.	Each	point	represents	a	separate	brain.	
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Figure	4.	A	-	C	and	D	-	F	show	ACE	protein	and	activity	with	respect	to	hypertensive	treatment	status,	with	
diagnosis	groups	combined	(column	1),	in	AD	(column	2)	and	controls	(column	3).	ACE	protein	was	significantly	
increased	in	treated	hypertensives	in	the	combined	diagnosis	(p	=	0.008)	and	AD	groups	(p	=	0.016).	The	
horizontal	bars	indicate	the	mean	and	SEM.	Each	point	represents	a	separate	brain.	
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Table	1	Summary	demographic	data	of	the	hypertensive	and	normotensive	AD	brains	and	hypertensive	
treated	and	untreated	AD	brains	used	in	the	retrospective	analysis	of	frontal	Aβ	load.	
	
	 	
	
	
age, y  ± s .d.  
gender,  F/M  
post-mortem delay,  h ± s .d.  
             
hypertensive group (N = 20) 
 
82.30 ± 5.01 
13/7 
37.15 ± 19.75 
normotensive group (N = 
62) 
 
79.42 ± 8.95  
38/24 
48.69 ± 25.33 
 
 
age,  y  ± s .d.  
gender,  F:M  
post-mortem delay,  h ± s .d.  
Braak tangle stage 	
treated	(N	=	9)	
	
83.89	±	5.21	
4/5	
43.56	±	22.27	
untreated	(N	=	11)	
	
81.00	±	4.67	
2/9	
31.91	±	16.65	
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Table	2	Summary	demographic	and	neuropathological	data	of	the	hypertensive	and	normotensive	AD	brains	
and	hypertensive	treated	and	untreated	AD	brains	used	in	the	retrospective	and	prospective	analysis	of	β-	and	
γ-secretase	activity,	respectively.	
	
	
	
	
age, y  ± s .d.  
gender,  F/M  
post-mortem delay,  h ± s .d.  
	
 
 
age,  y  ± s .d.  
gender,  F:M  
post-mortem delay,  h ± s .d.  
 
	
	
age, y  ± s .d.  
gender,  F:M  
post-mortem delay,  h ± s .d. 	
hypertensive	group	(N	=	31)	
	
82.97	±	6.96	
15/16	
41.45	±	23.95	
normotensive	group	(N	=	77)	
	
78.40	±	10.11	
44/33	
44.86	±	26.99	
	
AD	(N	=	18)	
	
82.50	±	5.25		
12/6	
35.28	±	19.89		
	
control	(N	=	13)	
	
83.62	±	9.01	
3/10	
50.00	±	27.15	
	
AD	(N	=	50)	
	
79.68	±	9.27	
31/19	
49.96	±	25.25		
	
control	(N	=	27)	
	
76.04	±	11.32		
13/14	
35.41	±	28.02		
	
treated	(N	=	13)	
	
85.85	±	5.96	
5/8	
40.85	±	22.21	
	
untreated	(N	=	17)	
	
80.89	±	7.04	
10/8	
41.89	±	25.76	
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Table	3	Summary	demographic	and	neuropathological	data	of	the	hypertensive	and	normotensive	AD	brains	
and	hypertensive	treated	and	untreated	AD	brains	used	in	the	retrospective	analysis	of	ACE,	IDE	and	NEP	
protein	and	activity.	
		 	
	   
	 hypertensive	group	(N	=	21)	 normotensive	group	(N	=	64)	
age, y  ± s .d.  83.57	±	7.57	 78.00	±	10.10		
gender,  F/M 11/10	 36/28	
post-mortem delay,  h ± s .d.  	35.71	±	22.57		 43.47	±	27.71	
 	
AD	(N	=	12)	
	
control	(N	=	9)	
	
AD	(N	=	43)	
	
control	(N	=	21)	
age, y  ± s .d.  83.08	±	4.58		 84.22	±	10.65	 79.72	±	9.44	 74.48	±	10.69		
gender,  F:M 9/3	 2/7	 27/16	 9/12	
post-mortem delay,  h ± s .d.  31.08	±	17.58		 41.89	±	27.80	 47.21	±	25.63		 35.81	±	30.77		
 	
treated	(N	=	9)	
	
	
untreated	(N	=	12)	
	 	
age, y  ± s .d.  87.22	±	5.12	 80.83	±	8.12	 	 	
gender,  F:M 3/6	 8/4	 	 	
post-mortem delay,  h ± s .d.  39.11	±	20.12	 33.17	±	24.80	 	
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Supplementary	Material	
	
	
	
Supplementary	Figure	1.	Box	and	whisker	plot	of	Braak	tangle	stages	in	the	hypertensive	and	normotensive	
group.	The	difference	between	groups	was	not	significant	(Mann-Whitney	U	test,	p	=	0.080)	but	it	was	
noteworthy	that	the	normotensive	group	included	a	few	cases	with	less	extensive	Braak	tangle	pathology.		
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Supplementary	Figure	2.	Frontal	Aβ	load	analysed	with	respect	to	the	absence	or	presence	of	APOE	ε4	in	AD	
cases	before	(A)	and	after	stratification	into	hypertensive	(HT)	and	normotensive	(NT)	cases	(B).	Frontal	Aβ	
load	was	not	significantly	greater	in	cases	with	one	or	two	APOE	ε4	alleles.	There	was	no	difference	in	the	
distribution	of	APOE	genotype	between	hypertensive	and	normotensive	cases	(data	not	shown).	Frontal	Aβ	
load	was	significantly	higher	in	the	ε4+	hypertensive	than	ε4+	normotensive	cases	(p	=	0.009).	The	horizontal	
bars	indicate	the	mean	and	SEM.	Each	point	represents	a	separate	brain.	
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Supplementary	Figure	3.	β-	(A)	and	γ-secretase	activities	(B)	in	midfrontal	cortex	in	AD	and	controls.	β-	
secretase	activity	was	significantly	higher	in	the	AD	group	(p	=	0.031).	A	similar	but	non-significant	trend	was	
found	for	γ-secretase	activity	(p	=	0.058).	The	horizontal	bars	indicate	the	mean	and	SEM.	Each	point	
represents	a	separate	brain.	
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Supplementary	Table	1	MRC	database	identifiers,	pathological	and	demographic	data	and	summary	of	measurements	available	for	individual	cases	included	in	all	
retrospective	analyses	and	prospective	analysis	of	γ-secretase	activity	in	relation	to	hypertensive	status.	
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HT/NT case 
number 
MRC ID Age (y)  gender post 
mortem 
delay 
(h) 
Braak 
tangle 
stage 
AOPE 
genotype 
diagnosis anti-
hypertensive 
treatment 
Frontal  
Aβ load 
β-
secretase 
activ ity  
γ-
secretase 
activ ity  
ACE 
protein 
ACE 
activ ity  
IDE 
protein 
IDE 
activ ity  
NEP 
protein 
NEP 
activ ity  
HT1 BBN_8644	 84	 M	 72	 III	 3.3	 C	 diuretic	 	 +	 +	 +	 +	 +	 +	 +	 +	
HT2 BBN_8651	 95	 F	 46	 II	 2.3	 C	 diuretic	 		 +	 +	 +	 +	 +	 +	 +	 +	
HT3 BBN_8964	 82	 F	 37	 II	 4.4	 C	 β-blocker,	CCB,	
diuretic	
		 +	 +	 +	 +	 +	 +	 +	 +	
HT4 BBN_8965	 80	 F	 21	 V	 3.4	 AD	 diuretic	 +	 +	 +	 +	 +	 +	 +	 +	 +	
HT5 BBN_8983	 78	 M	 48	 I	 3.3	 C	 CCB,	diuretic	 		 +	 +	 		 		 		 		 		 		
HT6 BBN_9106	 93	 M	 20	 VI	 3.3	 AD	 ACEI,	diuretic	 +	 +	 +	 		 		 		 		 		 		
HT7 BBN_9113	 81	 F	 59	 V	 3.4	 AD	 ACEI,	diuretic	 +	 		 		 		 		 		 		 		 		
HT8 BBN_9119	 80	 M	 49	 V	 3.4	 AD	 ACEI,	diuretic,	
nitrates	
+	 		 		 		 		 		 		 		 		
HT9 BBN_9136	 77	 F	 26	 VI	 3.4	 AD	 β-blocker,	CCB	 +	 +	 +	 	      
HT10 BBN_9200	 84	 M	 64	 V	 3.4	 AD	 CCB,	diuretic	 +	 +	 +	 +	 +	 +	 +	 +	 +	
HT11 BBN_9222	 90	 M	 32	 VI	 3.3	 AD	 nitrates	 +	 +	 +	 +	 +	 +	 +	 +	 +	
HT12 BBN_9248	 83	 F	 85	 VI	 4.4	 AD	 diuretic	 +	 +	 +	 	      
HT13 BBN_9275	 87	 M	 36	 VI	 4.4	 AD	 β-blocker	 +	 +	 +	 +	 +	 +	 +	 +	 +	
HT14 BBN_9299	 90	 M	 6	 II	 2.3	 C	 ACEI,	diuretic,	
nitrates	
		 +	 +	 +	 +	 +	 +	 +	 +	
HT15 BBN_9311	 93	 M	 38	 III	 2.3	 C	 ACEI,	CCB	 	 +	 +	 +	 +	 +	 +	 +	 +	
HT16 BBN_8639	 62	 M	 4	 0	 3.4	 C	 -	 		 +	 +	 +	 +	 +	 +	 +	 +	
HT17 BBN_8709	 83	 M	 86	 II	 3.3	 C	 -	 		 +	 +	 		 		 		 		 		 		
HT18 BBN_8723	 80	 M	 67	 III	 3.4	 C	 -	 		 +	 +	 		 		 		 		 		 		
HT19 BBN_8735	 88	 F	 72	 0	 3.3	 C	 -	 		 +	 +	 		 		 		 		 		 		
HT20 BBN_8757	 90	 M	 48	 II	 3.3	 C	 -	 	 +	 +	 +	 +	 +	 +	 +	 +	
HT21 BBN_8887	 89	 M	 91	 I	 3.4	 C	 -	 	 +	 +	 +	 +	 +	 +	 +	 +	
HT22 BBN_8906	 78	 F	 35	 VI	 3.3	 AD	 -	 +	 +	 +	 	      
HT23 BBN_8947	 78	 F	 4	 V	 3.3	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
HT24 BBN_8997	 74	 F	 12	 VI	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
HT25 BBN_9076	 84	 F	 20	 V	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
HT26 BBN_9150	 87	 F	 55	 V	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
HT27 BBN_9167	 79	 F	 48	 V	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
HT28 BBN_9261	 83	 M	 48	 V	 3.3	 AD	 -	 +	 +	 +	 		 		 		 		 		 		
HT29 BBN_9263	 74	 M	 48	 V	 2.3	 AD	 -	 +	 +	 +	 	      
HT30 BBN_9292	 73	 M	 35	 III	 3.3	 C	 -	 	 +	 +	 +	 +	 +	 +	 +	 +	
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HT31 BBN_9298	 83	 F	 32	 VI	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
HT32 BBN_9320	 87	 F	 28	 VI	 3.3	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
HT33 BBN_9323	 84	 F	 21	 VI	 2.3	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT1 BBN_8671	 78	 F	 24	 II	 3.3	 C	 -	 	 +	 +	 	      
NT2 BBN_8684	 71	 M	 25	 I	 3.3	 C	 -	 		 +	 +	 +	 +	 +	 +	 +	 +	
NT3 BBN_8691	 82	 F	 35	 III	 2.3	 C	 -	 	 +	 +	 	      
NT4 BBN_8702	 58	 M	 20	 0	 2.3	 C	 -	 		 +	 +	 		 		 		 		 		 		
NT5 BBN_8703	 64	 M	 16	 0	 3.3	 C	 -	 	 +	 +	 +	 +	 +	 +	 +	 +	
NT6 BBN_8706	 72	 M	 42	 I	 3.3	 C	 -	 		 +	 +	 +	 +	 +	 +	 +	 +	
NT7 BBN_8708	 90	 M	 45	 II	 2.3	 C	 -	 	 +	 +	 	      
NT8 BBN_8712	 81	 F	 103	 II	 3.3	 C	 -	 	 +	 +	 +	 +	 +	 +	 +	 +	
NT9 BBN_8717	 77	 M	 55	 I	 3.3	 C	 -	 		 +	 +	 +	 +	 +	 +	 +	 +	
NT10 BBN_8722	 78	 M	 12	 II	 3.3	 C	 -	 	 +	 +	 +	 +	 +	 +	 +	 +	
NT11 BBN_8725	 73	 M	 36	 II	 3.3	 C	 -	 	 +	 +	 +	 +	 +	 +	 +	 +	
NT12 BBN_8728	 88	 F	 62	 II	 3.3	 C	 -	 		 +	 +	 		 		 		 		 		 		
NT13 BBN_8732	 76	 F	 106	 II	 3.3	 C	 -	 	 +	 +	 +	 +	 +	 +	 +	 +	
NT14 BBN_8739	 93	 F	 18	 II	 3.3	 C	 -	 	 +	 +	 	      
NT15 BBN_8741	 80	 F	 92	 0	 3.3	 C	 -	 		 +	 +	 +	 +	 +	 +	 +	 +	
NT16 BBN_8749	 88	 F	 28	 II	 3.3	 C	 -	 	 +	 +	 +	 +	 +	 +	 +	 +	
NT17 BBN_8751	 82	 M	 30	 II	 3.3	 C	 -	 		 +	 +	 +	 +	 +	 +	 +	 +	
NT18 BBN_8770	 89	 F	 15	 II	 3.3	 C	 -	 		 +	 +	 +	 +	 +	 +	 +	 +	
NT19 BBN_8776	 73	 M	 33	 I	 2.3	 C	 -	 	 +	 +	 +	 +	 +	 +	 +	 +	
NT20 BBN_8819	 89	 F	 71	 V	 3.3	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT21 BBN_8825	 78	 F	 77	 VI	 4.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT22 BBN_8834	 78	 F	 9	 V	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT23 BBN_8835	 73	 F	 59	 I	 3.3	 C	 -	 	 +	 +	 +	 +	 +	 +	 +	 +	
NT24 BBN_8839	 82	 M	 69	 V	 4.4	 AD	 -	 +	 		 		 		 		 		 		 		 		
NT25 BBN_8841	 81	 F	 80	 III	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT26 BBN_8842	 81	 F	 42	 VI	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT27 BBN_8845	 91	 F	 37	 IV	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
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NT28 BBN_8848	 77	 F	 43	 IV	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT29 BBN_8852	 71	 F	 67	 V	 4.4	 AD	 -	 +	 +	 +	 	      
NT30 BBN_8853	 96	 F	 53	 IV	 2.3	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT31 BBN_8857	 87	 F	 72	 V	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT32 BBN_8870	 87	 F	 67	 V	 2.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT33 BBN_8871	 79	 F	 70	 III	 3.3	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT34 BBN_8872	 88	 F	 79	 VI	 3.3	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT35 BBN_8885	 68	 M	 28	 V	 3.3	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT36 BBN_8886	 81	 M	 29	 IV	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT37 BBN_8892	 91	 F	 70	 V	 2.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT38 BBN_8898	 83	 F	 24	 II	 3.3	 C	 -	 	 +	 +	 +	 +	 +	 +	 +	 +	
NT39 BBN_8905	 72	 M	 61	 IV	 3.4	 AD	 -	 +	 +	 +	 		 		 		 		 		 		
NT40 BBN_8912	 82	 F	 24	 VI	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT41 BBN_8915	 85	 M	 58	 IV	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT42 BBN_8916	 83	 F	 43	 V	 3.4	 AD	 -	 +	 +	 +	 		 		 		 		 		 		
NT43 BBN_8917	 91	 M	 43	 III	 3.3	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT44 BBN_8918	 89	 F	 82	 V	 3.3	 AD	 -	 +	 +	 +	 		 		 		 		 		 		
NT45 BBN_8923	 82	 M	 3	 II	 3.3	 C	 -	 	 +	 +	 +	 +	 +	 +	 +	 +	
NT46 BBN_8930	 70	 F	 25	 VI	 3.4	 AD	 -	 +	 		 		 		 		 		 		 		 		
NT47 BBN_8949	 79	 M	 24	 0	 3.3	 C	 -	 		 +	 +	 +	 +	 +	 +	 +	 +	
NT48 BBN_8954	 69	 M	 48	 V	 4.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT49 BBN_8956	 43	 F	 12	 0	 3.3	 C	 -	 		 +	 +	 +	 +	 +	 +	 +	 +	
NT50 BBN_8958	 74	 M	 50	 V	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT51 BBN_8966	 53	 M	 7	 III	 3.3	 C	 -	 		 +	 +	 +	 +	 +	 +	 +	 +	
NT52 BBN_8980	 72	 F	 24	 0	 3.3	 C	 -	 	 +	 +	 +	 +	 +	 +	 +	 +	
NT53 BBN_9005	 89	 F	 4	 VI	 3.4	 AD	 -	 +	 		 		 		 		 		 		 		 		
NT54 BBN_9026	 79	 M	 28	 VI	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT55 BBN_9031	 85	 M	 66	 VI	 3.4	 AD	 -	 +	 +	 +	 		 		 		 		 		 		
NT56 BBN_9037	 81	 F	 66	 IV	 3.3	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT57 BBN_9043	 80	 M	 31	 VI	 3.4	 AD	 -	 +	 		 		 		 		 		 		 		 		
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NT58 BBN_9050	 90	 F	 21	 IV	 4.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT59 BBN_9092	 75	 M	 6	 III	 2.3	 C	 -	 	 +	 +	 +	 +	 +	 +	 +	 +	
NT60 BBN_9112	 74	 F	 53	 V	 4.4	 AD	 -	 +	 	        
NT61 BBN_9114	 82	 M	 64	 IV	 3.3	 AD	 -	 +	 	        
NT62 BBN_9125	 84	 F	 23	 VI	 4.4	 AD	 -	 +	 	        
NT63 BBN_9132	 80	 M	 5	 V	 3.4	 AD	 -	 +	 		 		 		 		 		 		 		 		
NT64 BBN_9156	 79	 M	 39	 V	 4.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT65 BBN_9165	 60	 F	 68	 VI	 3.3	 AD	 -	 +	 		 		 		 		 		 		 		 		
NT66 BBN_9182	 74	 M	 24	 V	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT67 BBN_9188	 68	 F	 87	 VI	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT68 BBN_9189	 78	 F	 21	 VI	 4.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT69 BBN_9193	 79	 M	 84	 V	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT70 BBN_9194	 89	 F	 39	 V	 4.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT71 BBN_9201	 65	 M	 90	 VI	 3.3	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT72 BBN_9205	 85	 F	 85	 VI	 3.4	 AD	 -	 +	 	        
NT73 BBN_9207	 80	 F	 71	 VI	 3.3	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT74 BBN_9209	 73	 F	 38	 V	 4.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT75 BBN_9212	 65	 F	 22	 VI	 3.3	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT76 BBN_9221	 68	 M	 61	 VI	 3.3	 AD	 -	 +	 +	 +	 	      
NT77 BBN_9242	 85	 F	 14	 IV	 3.3	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT78 BBN_9243	 88	 F	 75	 V	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT79 BBN_9265	 60	 F	 5	 VI	 -	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT80 BBN_9269	 83	 M	 99	 IV	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT81 BBN_9284	 76	 F	 43.5	 VI	 3.4	 AD	 -	 +	 	        
NT82 BBN_9291	 62	 M	 25	 VI	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT83 BBN_9293	 78	 M	 50	 VI	 3.4	 AD	 -	 +	 		 		 		 		 		 		 		 		
NT84 BBN_9295	 85	 M	 50	 VI	 3.3	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT85 BBN_9296	 98	 F	 21	 V	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT86 BBN_9301	 84	 F	 11	 V	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT87 BBN_9303	 69	 M	 12	 V	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
37	
	
Supplementary	Table	2	Non-parametric	analysis	of	frontal	Aβ	load	and	of	Aβ–synthesising	and	–degrading	
enzymes	in	relation	to	post-mortem	delay	
Dataset vs post-
mortem delay 
Spearman Mann-Whitney 
test 
p value 
Frontal  Aβ load 
β-secretase activ ity  
γ-secretase activ ity  
0.755	 0.035	
0.963	 -0.005	
0.677	 -0.041	
ACE protein 
ACE activ ity 
IDE protein 
0.309	 0.112	
0.499	 0.156	
0.211	 0.137	
IDE activ ity 
NEP protein 
NEP activ ity  
0.114	 -0.173	
0.571	 0.062	
0.789	 0.029	
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Supplementary	Table	3	Non-parametric	analysis	of	levels	and	activity	of	Aβ-degrading	enzymes	in	
hypertensive	and	normotensive	groups,	with	diagnosis	groups	combined,	in	AD	and	in	controls.	
Dataset compared 
between hypertensive 
and normotensive 
group 
cohort Mann-Whitney 
test 
p value 
ACE protein combined	 0.001**	
AD	 0.009**	
control	 0.856	
ACE activ ity combined	 0.239	
AD	 0.783	
control	 0.587	
IDE protein combined	 0.036	
AD	 0.233	
control	 0.148	
IDE act iv ity combined	 0.208	
AD	 0.799	
control	 0.027*	
NEP protein combined	 0.412	
AD	 0.927	
control	 0.258	
NEP activ ity  combined	 0.676	
AD	 0.508	
control	 0.189	
*significant	at	the	95%	confidence	interval,	**	significant	at	the	99%	confidence	interval	
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Supplementary	Table	4	Non-parametric	analysis	of	levels	and	activity	of	Aβ-degrading	enzymes	in	treated	and	
untreated	hypertensive	groups,	with	diagnosis	groups	combined,	in	AD	and	in	controls.	
	
Dataset compared 
between hypertensive 
treated and hypertensive 
untreated group 
cohort Mann-Whitney 
test 
p value 
ACE protein combined	 0.008**	
AD	 0.016*	
control	 0.286	
ACE activ ity combined	 0.500	
AD	 0.683	
control	 0.905	
IDE protein combined	 0.594	
AD	 0.683	
control	 0.191	
IDE act iv ity combined	 0.749	
AD	 0.808	
control	 0.905	
NEP protein combined	 0.859	
AD	 0.461	
control	 1.000	
NEP activ ity  combined	 0.749	
AD	 0.570	
control	 0.730	
*significant	at	the	95%	confidence	interval,	**	significant	at	the	99%	confidence	interval	
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ACE	=	angiotensin-converting	enzyme;	ACEI	=	angiotensin-converting	enzyme	inhibitor;	AD	=	Alzheimer’s	disease;	C	=	control;	CCB	=	calcium	channel	blocker;	HT	=	
hypertensive;	IDE	=	insulin-degrading	enzyme;	NEP	=	neprilysin;	NT	=	normotensive;	-	=	untreated;	+	=	measured	
	
NT88 BBN_9304	 61	 M	 38	 V	 3.4	 AD	 -	 +	 +	 +	 +	 +	 +	 +	 +	 +	
NT89 BBN_9309	 88	 F	 88	 V	 3.3	 AD	 -	 +	 +	 +	 		 		 		 		 		 		
